ABSCI CORPORATION - COMMON STOCK

Absci to Participate in Upcoming Investor Conferences

24 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024

15 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Absci to Participate in Upcoming Investor Conferences

21 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Absci Reports Business Updates and Second Quarter 2024 Financial and Operating Results

14 Aug 2024 13:01:00 By Nasdaq GlobeNewswire

Absci Collaborates with Global Cancer Center to Discover Novel Therapeutics Using Generative AI

12 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024

10 Jul 2024 05:00:00 By Nasdaq GlobeNewswire

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

03 Jul 2024 13:00:00 By Nasdaq GlobeNewswire

Absci to Participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit

12 Jun 2024 05:00:00 By Nasdaq GlobeNewswire

Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

28 May 2024 05:00:00 By Nasdaq GlobeNewswire

Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results

14 May 2024 04:30:00 By Nasdaq GlobeNewswire

Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024

16 Apr 2024 05:00:00 By Nasdaq GlobeNewswire

Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference

28 Mar 2024 13:05:00 By Nasdaq GlobeNewswire

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

21 Mar 2024 04:30:00 By Nasdaq GlobeNewswire

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

01 Mar 2024 13:01:00 By Nasdaq GlobeNewswire

Absci Announces Pricing of Public Offering of Common Stock

27 Feb 2024 19:20:52 By Nasdaq GlobeNewswire

Absci Announces Proposed Public Offering of Common Stock

27 Feb 2024 13:01:00 By Nasdaq GlobeNewswire

Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI

21 Feb 2024 04:30:00 By Nasdaq GlobeNewswire

Absci to Participate in Upcoming Investor Conferences

20 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Absci Appoints Professor Sir Mene Pangalos to its Board of Directors

10 Jan 2024 04:30:00 By Nasdaq GlobeNewswire

Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

08 Jan 2024 04:00:00 By Nasdaq GlobeNewswire